The imbalance between HAT and HDAC in favor of the latter, which manifests in most types of cancer and is associated with an alteration in gene expression [32,33], spurred the clinical development of HDACi with the aim to re-adjust the HAT/HDAC ratio. This evidence concerns the gene TMPRSS11D and cancer.